Maze Therapeutics, Inc. MAZE

MAZE Company Overview

Maze Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing precision medicines for patients with genetically defined diseases. The company operates within the biotechnology and rare disease therapeutics industries, with a strategy centered on identifying genetic modifiers of disease and translating those insights into targeted therapies. Maze uses a proprietary human genetics-driven discovery platform, commonly referred to as the Compass platform, to identify novel drug targets and develop small-molecule therapies for renal, metabolic, and cardiovascular diseases.

The company’s primary value drivers are its internally developed therapeutic candidates and its genetics-based drug discovery capabilities. Maze has concentrated much of its development activity on chronic kidney disease and related metabolic disorders, including APOL1-associated kidney disease. Founded in 2017 and headquartered in South San Francisco, California, the company was established by a group of biotechnology entrepreneurs and scientists seeking to apply large-scale human genetic data to drug discovery. Maze has evolved from an early discovery-stage platform company into a publicly traded clinical-stage biotechnology enterprise with multiple development programs and strategic industry collaborations.